Mallinckrodt PLC - ESG Rating & Company Profile powered by AI
Detailed ESG assessment of Mallinckrodt PLC are accessed by registering for free. The webpage contains a free Sustainability analysis for Mallinckrodt PLC. The assessment of Mallinckrodt PLC leverages intelligence from across the web as well as from public filings by Mallinckrodt PLC.
Mallinckrodt PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.6; made up of an environmental score of 0.0, social score of 2.7 and governance score of 8.0.
3.6
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1132 | Taro Pharmaceutical Industries Ltd | 3.7 | Medium |
| 1132 | Traphaco JSC | 3.7 | Medium |
| 1144 | Mallinckrodt PLC | 3.6 | Medium |
| 1144 | CellSeed Inc | 3.6 | Medium |
| 1144 | Cellectar Biosciences Inc | 3.6 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Mallinckrodt PLC have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Mallinckrodt PLC disclose current and historical energy intensity?
Sign up for free to unlockDoes Mallinckrodt PLC report the average age of the workforce?
Sign up for free to unlockDoes Mallinckrodt PLC reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Mallinckrodt PLC disclose its ethnicity pay gap?
Sign up for free to unlockDoes Mallinckrodt PLC disclose cybersecurity risks?
Sign up for free to unlockDoes Mallinckrodt PLC offer flexible work?
Sign up for free to unlockDoes Mallinckrodt PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Mallinckrodt PLC disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Mallinckrodt PLC conduct supply chain audits?
Sign up for free to unlockDoes Mallinckrodt PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Mallinckrodt PLC conduct 360 degree staff reviews?
Sign up for free to unlockDoes Mallinckrodt PLC disclose the individual responsible for D&I?
Sign up for free to unlockDoes Mallinckrodt PLC disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Mallinckrodt PLC disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Mallinckrodt PLC disclose water use targets?
Sign up for free to unlockDoes Mallinckrodt PLC have careers partnerships with academic institutions?
Sign up for free to unlockDid Mallinckrodt PLC have a product recall in the last two years?
Sign up for free to unlockDoes Mallinckrodt PLC disclose incidents of discrimination?
Sign up for free to unlockDoes Mallinckrodt PLC allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Mallinckrodt PLC issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Mallinckrodt PLC disclose parental leave metrics?
Sign up for free to unlockDoes Mallinckrodt PLC disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Mallinckrodt PLC disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Mallinckrodt PLC disclose the pay ratio of women to men?
Sign up for free to unlockDoes Mallinckrodt PLC support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Mallinckrodt PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Mallinckrodt PLC reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Mallinckrodt PLC involved in embryonic stem cell research?
Sign up for free to unlockDoes Mallinckrodt PLC disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Mallinckrodt PLC disclose its waste policy?
Sign up for free to unlockDoes Mallinckrodt PLC report according to TCFD requirements?
Sign up for free to unlockDoes Mallinckrodt PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Mallinckrodt PLC disclose energy use targets?
Sign up for free to unlockDoes Mallinckrodt PLC disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Mallinckrodt PLC have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Mallinckrodt PLC
These potential risks are based on the size, segment and geographies of the company.
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers Acthar Gel, an injectable drug for rheumatoid arthritis, multiple sclerosis, infantile spasms, systemic lupus erythematosus, polymyositis, and others; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an acetaminophen injection; Therakos photopheresis, an immunotherapy treatment platform; and Amitiza for constipation. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; StrataGraft, which is in Phase III and II clinical development for the treatment of burns; MNK-6105 and MNK-6106, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; and SLN500, a ribonucleic acid technology therapy. In addition, it offers specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc for the development and commercialization of ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland. On October 12, 2020, Mallinckrodt plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.